Sugi Predict

Sugi Predict / Compounds / SCHEMBL2925701

SCHEMBL2925701

SCHEMBL2925701

O=C(O)N1CCN(Cc2cccc(O)c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.59
▸ HPGD P15428 1/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ HBB P68871 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ LMNA P02545 3/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ DRD2 P14416 1/20 0.56
▸ DRD3 P35462 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ TSHR P16473 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ BCL2L1 Q07817 1/20 0.53
▸ SIGMAR1 Q99720 1/20 0.53
▸ KDM4E B2RXH2 2/20 0.51
▸ HTT P42858 1/20 0.51
▸ CA12 O43570 1/20 0.51
▸ CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19049378 0.86 HRH3 (0.60) ALDH1A1HPGDALOX15HBBHSD17B10
SCHEMBL4828824 0.84 LMNA (0.56) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL24827586 0.84 ALDH1A1 (0.52) ALDH1A1HPGDALOX15HBBHSD17B10
SCHEMBL19002668 0.84 ALDH1A1 (0.58) ALDH1A1HPGDALOX15HBBHSD17B10
SCHEMBL5571317 0.83 LMNA (0.46) ALDH1A1HPGDALOX15HBBHSD17B10
SCHEMBL2850013 0.83 ALDH1A1 (0.70) ALDH1A1HPGDLMNASMN1; SMN2KMT2A
SCHEMBL2930424 0.83 SIGMAR1 (0.73) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL3093924 0.83 FAAH (0.70) ALDH1A1ALOX15SMN1; SMN2KMT2AMEN1
SCHEMBL3047497 0.83 KDM4E (0.71) ALDH1A1HPGDLMNASMN1; SMN2KMT2A
SCHEMBL4838001 0.83 CYP2D6 (0.73) ALDH1A1HPGDALOX15HBBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112368270-B Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer 卫材R&D管理有限公司 2023-10-13 — — CN claimed
CN-101448844-B Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE 2012-07-25 — — CN claimed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 — — EP claimed
CN-101448844-A Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE (CH) 2009-06-03 — — CN claimed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 — — EP claimed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 — — WO claimed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 — — US claimed
CN-117285502-A Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer 卫材R&D管理有限公司 2023-12-26 — — CN disclosed
CN-112368270-B Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer 卫材R&D管理有限公司 2023-10-13 — — CN disclosed
CN-101448844-B Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE 2012-07-25 — — CN disclosed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 — — EP disclosed
CN-101686979-A The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces JANSSEN PHARMACEUTICA NV 2010-03-31 — — CN disclosed
CN-101448844-A Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE (CH) 2009-06-03 — — CN disclosed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 — — WO disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 — — US disclosed
US-20060166971-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. (NL) 2006-07-27 — — US disclosed
US-20050032777-A1 Diazacycloalkanes as oxytocin agonists FEERING B.V. (NL) 2005-02-10 — — US disclosed
EP-1449844-A1 benzamide derivatives as oxytocin agonists and vasopressin antagonists FERRING B.V. (NL) 2004-08-25 — — EP disclosed
EP-1421087-A1 DIAZACYCLOALKANES AS OXYTOCIN AGONISTS FERRING B.V. (NL) 2004-05-26 — — EP disclosed
WO-2003016316-A1 DIAZACYCLOALKANES AS OXYTOCIN AGONISTS FERRING B.V. (NL) 2003-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032777-A1 Diazacycloalkanes as oxytocin agonists OXTR, GNRHR, KISS1R ALDH1A1 3597/4885HPGD 1137/4885ALOX15 1538/4885
US-20060166971-A1 Benzamide derivatives as oxytocin agonists and vasopressin antagonists AVPR1A, AVPR2, AVPR1B ALDH1A1 2308/4885HPGD 1596/4885ALOX15 1467/4885
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives ADORA2B, UTS2R, TBXA2R ALDH1A1 676/4885HPGD 1175/4885ALOX15 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.